Learn what proteolysis-targeting chimeras (PROTACs) are, how they work as small-molecule protein degraders, and why they outperform classic inhibitors by accessing undruggable targets, driving deep protein knockdown, and enabling next-generation cancer therapies like ARV-110.
Learn what PROTACs (proteolysis-targeting chimeras) are, how they work via the ubiquitin–proteasome system, and why protein degraders can outperform traditional small molecule inhibitors in oncology and beyond.
Learn how targeted protein degradation (TPD) uses PROTACs and molecular glue degraders to hijack the ubiquitin–proteasome system, eliminate disease-causing proteins, and expand the “druggable” proteome beyond traditional small molecule inhibitors.
Learn how targeted protein degraders, especially PROTACs, are transforming small molecule drug discovery by degrading disease‑driving proteins, expanding druggable targets beyond classical enzyme and receptor inhibition.
Learn how PROTAC small molecules are redefining cancer therapy by harnessing targeted protein degradation to eliminate “undruggable” oncogenic drivers, overcome resistance, and expand the frontier of small molecule oncology.
Discover why KRAS became the iconic “undruggable” oncogene in cancer biology, how covalent KRASG12C inhibitors like sotorasib and adagrasib opened the door, and what’s next for targeting common KRAS mutations such as G12D and G12V in lung, pancreatic, and colorectal cancers.